NCT07547878Enrolling by invitationPhase 4
Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)
A Pilot Randomized Clinical Trial to Assess Feasibility, Safety, and Efficacy of Rapid, Simultaneous Therapy Initiation in Chronic Kidney Disease and Type 2 Diabetes: RAPID-CKD
Source: ClinicalTrials.gov · Last updated 13 Oct 2026
Brief summary (registry, in English)
The goal of this clinical trial is to learn if starting four kidney disease medicines quickly and together (a rapid treatment approach) is safe and works well in people with type 2 diabetes and chronic kidney disease. The main questions it aims to answer are: * Is it safe to start these medicines over a short period of time? * How often do kidney function changes or high potassium levels occur? * Does this approach lower protein in the urine (a sign of kidney damage)? * How many participants are able to stay on all four medicines over 6 months? Researchers will compare this approach to usual care, where medicines are started one at a time over several months. Participants will: Be assigned by chance to either this approach or usual care Start up to four approved kidney medicines over about 8 weeks (rapid treatment approach) or follow standard care Have regular clinic visits and lab tests to check kidney function and potassium levels Be followed for about 6 months
- Status (registry)
- Enrolling by invitation
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 64 (estimated)
- First submitted
- 17 Apr 2026
- Start date
- 8 Apr 2026
- Primary completion date
- 31 Mar 2029
- Lead sponsor
- Baylor Research Institute
- Diseases
- Chronic kidney disease, Type 2 diabetes
- NCT number
- NCT07547878
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 64
- From 8 Apr 2026 to the primary completion date, 31 Mar 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Type 1 diabetes
- any known primary non-diabetic kidney disease (i.e., polycystic kidney disease, glomerulonephritis, interstitial nephritis, etc.)
- history of kidney transplant
- known hypersensitivity to any study drug
- active malignancy or infection
- brittle diabetes (defined as severe glycemic instability with hospitalization or emergency care for hypoglycemia or hyperglycemia within the past 6 months)
- SGLT2i: diabetic ketoacidosis, type 1 diabetes, recurrent genitourinary infections
- GLP1-RA: personal or family history of medullary thyroid carcinoma, known gastroparesis, or pancreatitis.
Lab values
- liver disease (i.e., aspartate transaminase or alanine transaminase \>5 times, or bilirubin \>3 times the upper limit of normal)
- serum potassium \>5.5 mEq/L at baseline
Other
- life expectancy \<6 months
- high-risk of hypoglycemia (Clarke or Gold score ≥4)
- predicted 12-month risk of hypoglycemia related emergency visits or hospitalizations \>5% using the Kaiser Permanente hypoglycemia prediction score
- high dose insulin use (\>1 unit/kg/day).
- RASi: hyperkalemia or angioedema
- ns-MRA: hyperkalemia
Who the study is looking for
- Patients aged 18-84 years
- eGFR 45 to ≤90 mL/min/1.73 m2
- UACR \>200 mg/g
- diagnosis of T2D
- receiving ≤2 guideline-recommended drug classes irrespective of dose for ≥4 weeks prior to screening
- eligible for all 4 drugs
- systolic BP (SBP) \>90 mmHg
- those willing to provide written informed consent and to adhere to study visits.
Age in the registry: 18 years to 84 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Baylor Scott and White Medical Center Temple Coordinator of this site? Confirm its status | Temple | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.